The Expression Level of Molecular Markers that Predict the Effect of Hepatocellular Carcinoma Undergoing Molecular Target Therapy

Trial Profile

The Expression Level of Molecular Markers that Predict the Effect of Hepatocellular Carcinoma Undergoing Molecular Target Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Sorafenib (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top